ABSTRACT Emerging viruses (EV) constantly arise from zoonotic reservoirs to threaten global health and economic stability, illustrated by the ongoing COVID19 pandemic that has infected over 220 million people and caused over 4.8 million deaths worldwide. The Administrative and Management Core (Adman Core A) is specifically responsive to this RFA and is structured to manage and coordinate all activities conducted by the five projects (PR1-5) and three scientific cores (Cores B-D) housed within the Rapidly Emerging Antiviral Drug Development Initiatives AViDD Center (READDI-AC). Core A has five specific aims that provide: (Aim 1) decisive leadership, administrative and financial oversight; (Aim 2) communication links between projects and cores, corporate partners, the NIH, and external collaborators/advisors; (Aim 3) data management and security across the Center; (Aim 4) the management structure needed to review research progress, identify problems, periodically review targets, and prioritize hits and leads for further development; and (Aim 5) pilot and mentored award management. In addition, Adman Core A will accelerate drug development and build capacity through the open sharing of reagents, tools, assays, and models that catalyze robust in vitro and in vivo assays for emerging viruses. Adman Core A manages a diverse team of academic and industry partners with deep expertise in antiviral drug discovery from multiple fields, including virologists, biochemists, structural biologists, enzymologists, pharmacologists, modelers, and medicinal chemists. Importantly, Adman Core A also engages pharmaceutical leaders, specifically Takeda, J&J, Chimerix, and Pardes Biosciences, who contribute in-kind resources, assays, chemical assets, chemistry, expertise, and leadership. The program takes an innovative approach to drug development that includes an early open science platform as promoted by the Structural Genomics Consortium, but then transitions to encourage intellectual property protection of chemical assets being formulated for preIND and IND enabling studies. By leveraging the combined assets and resources of our corporate and academic partners, Adman Core A’s overall goal is to advance at least 2 DAA drugs to the milestone of a pre-IND meeting with the FDA